115 results about "Apigetrin" patented technology

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention discloses a yeast engineering bacterium for producing apigenin and application thereof. The yeast engineering bacterium comprises a yeast genome, a whole-cell catalytic synthesis apigenin module, a heterologous apigenin biosynthesis path and an NADPH supply module, the whole-cell catalytic synthesis apigenin module comprises an FNSI coding gene and an FNSII coding gene; the heterologous apigenin biosynthesis path comprises a TAL coding gene, a 4CL coding gene, a CHS coding gene, a CHI coding gene and an FNSII coding gene; the NADPH supply module comprises a G6PD coding gene and a PGD coding gene; the method disclosed by the invention has the characteristics of greenness and safety, and lays a foundation for synthesizing apigenin in a yeast cell factory.

The invention discloses a preparation method of a peony seed shell flavone extract, which comprises the following steps: extracting peony seed shell flavone (ZKHT) by adopting enzymolysis-ultrasonic extraction, and separating and purifying by using a resin adsorption combined membrane separation technology, so that various flavonoid active compounds such as kaempferol, luteolin and apigenin with high content in peony seed shells can be effectively extracted at the same time; the method provided by the invention provides technical support for reutilization of the peony seed shell waste, and realizes efficient and comprehensive utilization of the peony seeds and by-products thereof.

The invention provides an apigenin nanoparticle preparation as well as a preparation method and application thereof. The preparation method comprises the following steps: weighing apigenin, dissolving the apigenin in an acetone solution containing a polylactic acid-glycolic acid copolymer, or dissolving the apigenin in an acetone solution containing the polylactic acid-glycolic acid copolymer and Eudragit S100, and uniformly stirring and mixing at room temperature to obtain a mixed solution; dropwise adding the mixed solution into a polyvinyl alcohol solution, carrying out ultrasonic treatment, and removing the solvent to prepare PANPs or PEANPs. The preparation method is simple, and the prepared PANPs and PEANPs are small in particle size and high in encapsulation efficiency, can effectively penetrate through intestinal epithelial barriers and promote internalization of apigenin into cells, have a good slow release characteristic, can remarkably improve the bioavailability of apigenin, and have a good treatment effect on inflammatory bowel diseases. PANPs has a better treatment effect on ulcerative colitis, and PEANPs has a better treatment effect on diffuse colitis.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention relates to the technical field of biology, in particular to application of lonidamine combined with apigenin to treatment of colorectal cancer. The invention provides a novel pharmaceutical composition for treating colorectal cancer. LND and AP form the pharmaceutical composition according to different molar concentrations or different weight ratios, the anti-tumor activity of the pharmaceutical composition is respectively tested on a colon cancer cell line MC38 culture and a tumor-bearing mouse, and results prove that compared with the effect of a single drug, the combined drug obviously improves the activity of anti-tumor cells in vitro or in vivo.

To provide a method for identifying a gene encoding an apiose transferase for converting apigenin into apiin and a gene encoding a glucose transferase, and consistently producing apiin from apigenin by using the apiose transferase and the glucose transferase encoded by the gene.SOLUTION: Provided is an apiose transferase including a specific amino acid sequence. Further, provided is a method for producing apiin from apigenin 7-O glucoside which includes a step of bringing the apiose transferase, apigenin 7-O glucoside and UDP-apiose in contact each other.SELECTED DRAWING: None

The invention discloses application of apigenin in preparation of a product for treating sjogren syndrome, and belongs to the technical field of medicines. The apigenin is used for remarkably regulating and controlling the immune system of the body, namely enhancing the immunosuppression function of MDSCs of the body, further inhibiting activation of dendritic cells DCs, resulting in reduction of the expression level of B cell activating factors BAFF, finally achieving the purposes of inhibiting B cell differentiation and reducing immunocompetence, and relieving the symptoms of SS.

The invention discloses radix tetrastigme flavone synthase and application thereof. The radix tetrastigme flavone synthase comprises an amino acid sequence as shown in SEQ ID No. 2. The key enzyme-flavone synthase gene (ThFNS) related to synthesis of apigenin in radix tetrastigme is cloned for the first time, in-vitro recombinant protein expression and enzymatic reaction system verification show that flavone synthase can catalyze naringenin to generate apigenin, and technical support is provided for follow-up metabolic engineering modification for an apigenin biosynthetic pathway.

The invention discloses an apigenin derivative as well as a preparation method and application thereof. The apigenin derivative has the following molecular structure expression, and the preparation method comprises the following steps: 1) in the presence of an optional catalyst, reacting p-coumaric acid with ethyl sulfonyl chloride to generate an intermediate 1; and 2) mixing the purified intermediate 1 with oxalyl chloride for reaction, carrying out acylating chlorination, adding apigenin, and carrying out stirring reaction in the presence of an acid-binding agent to obtain the apigenin derivat.The apigenin derivative is novel in structure and has good biological activity for reducing the blood uric acid level in vivo.

The present invention discloses a golden chrysanthemum flavonoid glycoside derived from golden chrysanthemum, wherein the golden chrysanthemum flavonoid glycoside is apigenin 7-O-(6"-O-malonyl)-β-D-glucoside derived from golden chrysanthemum. The present invention separates and purifies apigenin 7-O-(6"-O-malonyl)-β-D-glucoside from golden chrysanthemum for the first time, completes the first synthesis through a 5-step synthesis process with a total yield of 2.7%, and discovers for the first time that the compound has activity in improving hyperlipidemia and fatty liver in vitro and in vivo. Therefore, the compound can be used in the preparation of products for treating related diseases such as hyperlipidemia and fatty liver.

The invention provides a sensitizing camptothecin drug anti-tumor combined drug composition and application thereof, and particularly relates to application of an apigenin and camptothecin drug composition in preparation of anti-tumor drugs. A natural dietary supplement and an anti-tumor chemotherapeutic drug are creatively combined, a colorectal cancer in-vitro cell model is utilized to prove that the apigenin has the anti-tumor effect of sensitizing camptothecin drugs, the apigenin and the low-dose camptothecin drugs can activate a PI3K-AKT pathway and a dsDNA-cGAS-STING pathway, tumor immunogenic death is induced, and the apigenin has the anti-tumor effect. And the anti-tumor immune response is activated. The invention not only has the effects of reducing toxicity and enhancing efficacy on clinically applied camptothecin medicines, but also provides a new strategy for sensitizing colorectal cancer immunotherapy.

The invention discloses a flavone composition capable of preventing and improving atopic dermatitis and application of the flavone composition, and belongs to the field of medicines and cosmetics. Cell morphology observation and beta-hexosaminidase detection prove that apigenin and chrysin have a good effect of inhibiting large cell strain degranulation; scratch experiments prove that kaempferol has a good effect of promoting interstitial closure of human keratinocytes, and then detection of atopic dermatitis related factor expression discovers that apigenin, chrysin and kaempferol are compounded to have the potential of enhancing the soothing effect. And human body safety evaluation and efficacy experiments are further carried out to screen out the optimal proportion of the soothing effect. The invention explores the multi-target synergistic prevention and improvement effect of the flavonoid compound on the aspects of allergy resistance, inflammation resistance and barrier repair, and expands the application and development value of the flavonoid compound in soothing cosmetics.

The invention provides a universal technical method for detecting non-toxic Chinese herbal medicine based on UPLC-QTOF-MS, and relates to the field of traditional Chinese medicine detection and analysis. The method comprises the following steps: S1, crushing non-toxic traditional Chinese medicinal materials; s2, preparing a to-be-detected sample solution; s3, preparing a QC accompanying standard product; s4, carrying out liquid mass analysis on the to-be-detected sample; and S5, processing mass spectrum information data. The method is characterized in that the QC standard substance in the step S3 is one or more of araflavin, aurantio-obtusin, patchouli ketone, apigenin, mangiferin, ginsenoside Rg1 and timosaponin, and chromatography-mass spectrometry conditions are defined in the step S4. The method disclosed by the invention has the advantages that a universal technical method is established instead of aiming at each specific traditional Chinese medicine, and targeted identification and analysis are not solved, so that a unified system is formed by inspection and analysis of different non-toxic Chinese herbal medicines, and non-targeted identification and analysis can be realized according to result differences on the premise of controlling the method differences.

This invention belongs to the field of biomedical technology, and particularly relates to a pharmaceutical composition for treating cervical cancer and its preparation method. The pharmaceutical composition for treating cervical cancer of this invention comprises the following components: a apigenin derivative and acetylvalerin in a mass ratio of 1:(0.3~0.5). This invention obtains a apigenin derivative by introducing specific functional groups onto apigenin, which exhibits high pharmacological activity against cervical cancer; synergistically acting with acetylvalerin, it effectively kills cervical cancer cells while reducing damage to normal cells, thus providing a safer and more effective treatment option for cervical cancer patients.

The invention discloses an apigenin derivative, a preparation method and application of the apigenin derivative in uric acid lowering drugs, the apigenin derivative has a molecular structure expression shown in the specification, and research shows that the apigenin derivative can lower uric acid through the dual effects of generation inhibition and excretion promotion, has no obvious influence on 24-hour urine creatinine and is expected to have good kidney safety.

The invention provides a multi-layer core natural polyphenol algal gel candy for pets with oxidation resistance. The algal gel candy comprises a skin material and a multi-layer core material wrapped in the skin material, the formula of the skin material comprises the following components in parts by weight: 80-90% of algae gel, 1-5% of coconut powder and 0.05-0.1% of potassium sorbate; the core material comprises an inner layer, a middle layer and an outer layer, each layer is prepared by mixing 1-3% of one of apigenin, quercetin and luteolin with 1-5% of coconut powder, and natural polyphenols contained in the inner layer, the middle layer and the outer layer are different from one another; according to the algae gel candy, multiple layers of natural polyphenols are used as core materials to be combined with algae gel used as skin materials, and the gel candy with the functional multiple layers of cores is prepared; the candy has relatively strong antioxidant ability, can effectively remove free radicals in the body and delay senescence so as to improve the immunity of the body, and has a wide market application prospect.

The invention relates to the technical field of medicines, and discloses a traditional Chinese medicine composition for treating diabetic retinopathy and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 25-35 parts of astragalus membranaceus, 3-9 parts of rheum officinale, 10-20 parts of salvia miltiorrhiza, 3-9 parts of roasted herba epimedii, 10-20 parts of dried motherwort and 2-4 parts of scalded leech. Research results show that in a db / db mouse DR model, the traditional Chinese medicine composition can enhance the structural integrity of a retina layer, especially INL and ONL. The effect is mediated by the quercetin and the apigenin in the traditional Chinese medicine composition by regulating an HIF-1alpha-VEGFA (High Intensity Factor 1 alpha-vascular endothelial growth factor A) pathway in macrophages, and the HIF-1alpha-VEGFA pathway plays a crucial role in reducing retinal leakage and subsequently slowing down the progress of diabetic retinopathy.

The present invention discloses apigenin 8-hydroxylase protein and its encoding gene and application. The apigenin 8-hydroxylase protein provided by the present invention is a) or b) protein as follows: a) a protein composed of the amino acid sequence shown in sequence 2 in the sequence list; b) a protein derived from a) with apigenin 8-hydroxylase activity, in which one or more amino acid residues are substituted and / or deleted and / or added to the amino acid sequence shown in sequence 2 in the sequence list. The present invention is based on the third-generation and second-generation transcriptome data of Lysionotus pauciflorus, and uses a reverse genetics method to find and identify the specific hydroxylation modification enzyme LpCYP82D‑1 synthesized by isobaicalein, providing apigenin 8-hydroxylase protein and its encoding sequence and experimental basis for the biosynthesis of isobaicalein.

The invention relates to the technical field of plant extraction, in particular to a rose extract. The rose extract comprises at least one of monomer ellagic acid, urolithin M5 and apigenin. The preparation method comprises the following steps: uniformly mixing rose powder with the ternary synergistic solvent, carrying out ultrasonic treatment for 10-60 minutes under the ultrasonic power of 150-250 W, and then stirring for 1-5 hours at the temperature of 20-50 DEG C; centrifuging and collecting supernate to obtain the rose extract. The rose flower extract provided by the invention has relatively strong inhibition capability on human pancreatic lipase.

This invention belongs to the field of pharmaceutical technology and specifically relates to the use of apigenin derivatives in the preparation of anti-tumor drugs. The structure of the apigenin derivative is shown below: wherein the groups are defined as described in the specification. The compounds of this invention effectively inhibit the proliferation of renal cancer Caki-1 cells, human gastric cancer cells SNU-5, lung cancer cells, and human colon cancer cells HCT 116 in vitro. They also exhibit good inhibitory activity against renal cancer Caki-1 cells in vivo, demonstrating promising application prospects.

The invention discloses a cardiospermum halicacabum extract, which is prepared by the following steps: (1) taking cardiospermum halicacabum powder, adding 70-90% ethanol aqueous solution, heating and refluxing for 40-50 minutes under the condition of 65-71 DEG C, and filtering to obtain filtrate and decoction dregs; (2) flushing the medicine residues with a 70-90% ethanol aqueous solution to obtain a flushing solution, combining the flushing solution with the filtrate obtained in the step (1) to obtain a combined filtrate, adding the 70-90% ethanol aqueous solution into the combined filtrate to complement the weight lost due to ethanol volatilization, shaking uniformly, and filtering to obtain a supernatant; and (3) enabling the supernate obtained in the step (2) to pass through a microfiltration membrane with the size of 0.45 mu m. The preparation method of the cardiospermum halicacabum extract is simple, and the content of myricetin, luteolin and apigenin in the cardiospermum halicacabum extract is high. The invention further discloses application of the cardiospermum halicacabum extract in preparation of cosmetics or medicines for relieving light aging damage.

The application discloses a bacterial QS inhibitor and application thereof, and the active ingredient of the bacterial QS inhibitor is apigenin, and the use concentration is a sub-inhibitory concentration of target bacteria. The application first discovers and systematically proves that apigenin has a wide and significant inhibitory effect on a variety of bacterial QS systems and a spoilage phenotype regulated by the QS systems. Experiments show that under a sub-inhibitory concentration, the inhibition rate of apigenin on biofilm formation of pectobacterium is up to 96.33%, the inhibition rate of apigenin on synthesis of a signal molecule is up to 88.42%, and the inhibition rate of apigenin on a key virulence enzyme is more than 70%; the fresh-keeping effect of apigenin on food is significant, and the application of apigenin in the field of food fresh-keeping is expanded; and apigenin is a natural dietary ingredient and has high safety.

This invention discloses a apigenin-betaine compound and its preparation method. The compound uses apigenin (Api) as its core, with -O-(CH2) at the 7', 4', and / or 5-position hydroxyl groups. n -N + (CH3)2-CH2COO ‑ Fragment substitution (n=2~12, x=1~3) forms an internal salt-type zwitterionic structure. In preparation, apigenin is first reacted with bromool Br(CH2). n A mitsunobu reaction was performed on OH under triphenylphosphine / dialkyl azodicarbonate conditions to obtain mono / polysubstituted bromoalkoxylated apigenin; subsequently, nucleophilic substitution with N,N-dimethylglycine under alkaline conditions yielded the target product. This structure, possessing both a tunable alkyl chain and a betaine cation / anion pair, significantly enhances the solubility and hydration capacity of apigenin in aqueous / alcoholic media, strengthens its affinity and stability for biomembranes, thereby improving in vivo absorption and distribution and potentially maintaining its antioxidant and anti-inflammatory activities. The method is mild, with a wide solvent and temperature range, suitable for scale-up and formulation applications.

The invention discloses an application of apigenin-7-O-beta-D-glucuronide in preparation of a medicine for treating fundus diseases, and establishes a model of ischemic fundus diseases of guinea pigs and a model of eyeball conjunctival microcirculation disturbance of rabbits. The prevention and treatment effects of the apigenin-7-O-beta-D-glucuronide on fundus diseases and fundus lesions are researched, and an experimental basis is provided for clinical treatment of the fundus diseases by the apigenin-7-O-beta-D-glucuronide.

The present invention relates to new solid forms (NSF) of a flavonoid and a coformer. The NSF are co-amorphous solids of flavonoids and amino acids, as well as the solvates of said co-amorphous solids. The flavonoid is selected from quercetin, genistein, fisetin, apigenin, naringenin, rutin, diosmin, among others. The coformer is selected from lysine and arginine. The NSF have enhanced stability, solubility and pharmacological properties over parent polyphenols. The new solid forms are suitable to be used in pharmaceutical compositions, food products, nutritional supplements and the like.

The invention discloses a method for performing carbon glycoside deglycosylation by using a biological method. The invention provides application of the protein combination: application in splitting C-C glucosidic bonds; application in preparation of aglycones; the invention also relates to an application in converting glucoside into aglycone. The invention also relates to an application in converting isoorientin and isovitexin into luteolin and apigenin. The invention also relates to an application in converting isoorientin into luteolin. The invention also relates to an application in converting isovitexin into apigenin. Application in splitting C-C glucosidic bonds; the invention also relates to an application in converting mangiferin into mangiferin aglycone. The protein combination comprises an LE1 protein, an LE2 protein and an LE3 protein. The method has great application and popularization values in the production field of aglycones or aglycone derivatives and downstream products thereof.

The invention discloses application of apigenin and a preparation thereof in improving drought tolerance of wheat plants. The technical problem to be solved is how to improve the drought tolerance of wheat plants. The invention specifically discloses application of apigenin or salt thereof or solvate thereof in any one of the following aspects: A1) application in improving the drought tolerance of gramineous plants; a2) application in preparation of a product for improving the drought tolerance of gramineous plants. The drought tolerance of the wheat seedlings can be improved by applying the apigenin or the salt thereof or the solvate of the apigenin and the salt to the wheat seedlings, and the method can be used for industrial production.

The invention relates to the field of biological pharmacy, and discloses an application of an FABP5 protein target inhibitor in preparation of a product for treating cancers, and the inhibitor is apigenin 7-O-malonyl glucoside. The invention provides a novel cancer cell targeting therapeutic drug, the inhibitor inhibits proliferation of renal clear cell adenocarcinoma and subcutaneous tumor-bearing through precise targeting of FABP5 protein and can be applied to preparation of anti-renal clear cell adenocarcinoma and subcutaneous tumor-bearing drugs, and apigenin 7-O-malonyl glucoside can be used in combination with a PD-1 monoclonal antibody, so that the treatment effect is good. The inhibition effect is better, and a new treatment scheme is provided for the treatment of the kidney cancer.